Your browser doesn't support javascript.
loading
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
How, Jeffrey A; Jazaeri, Amir; Westin, Shannon N; Sood, Anil K; Ramondetta, Lois M; Xu, Mingxuan; Abonofal, Abdulrahman; Karp, Daniel D; Subbiah, Vivek; Stephen, Bettzy; Rodon, Jordi A; Yang, Fei; Naing, Aung.
Affiliation
  • How JA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jazaeri A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ramondetta LM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu M; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Abonofal A; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Karp DD; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Rodon JA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA.
  • Yang F; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.2026, Houston, TX, 77030, USA. anaing@mdanderson.org.
Invest New Drugs ; 39(3): 829-835, 2021 06.
Article in En | MEDLINE | ID: mdl-33415580
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antibodies, Monoclonal, Humanized / Immune Checkpoint Inhibitors / Granulosa Cell Tumor / Neoplasm Recurrence, Local Type of study: Guideline / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antibodies, Monoclonal, Humanized / Immune Checkpoint Inhibitors / Granulosa Cell Tumor / Neoplasm Recurrence, Local Type of study: Guideline / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 2021 Type: Article Affiliation country: United States